Análisis de la eficacia de las distintas estrategias | 20 ENE 17

¿Cuál es el valor de la angioplastia coronaria en el paciente estable?

Hasta el momento la estrategia terapéutica debería ser el tratamiento farmacológico óptimo en lugar de la angioplastia
Autor/a: Weintraub WS, Boden WE Fuente: JAMA Intern Med. doi:10.1001/jamainternmed.2016.3071 Reexamining the Efficacy and Value of Percutaneous Coronary Intervention for Patients With Stable Ischemic Heart Disease
INDICE:  1. Página 1 | 2. Referencias
Referencias

REFERENCIAS

1. Hume D. An Enquiry Concerning Human Understanding. 1748.

2. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: a New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.

3. Redberg RF. Evidence, appropriateness, and technology assessment in cardiology: a case study of computed tomography. Health Aff (Millwood).2007;26(1):86-95.

4. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1(8058):263.

5. Fischman DL, Leon MB, Baim DS, et al; Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331(8):496-501.

6. Morice MC, Serruys PW, Sousa JE, et al; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346 (23):1773-1780.

7. PriceMJ, Angiolillo DJ. Platelet inhibitor agents. In: Topol EJ, Teirstein PS, eds. Textbook of Interventional Cardiology. 7th ed. Philadelphia, PA: Elsevier; 2016:151-204.

8. Eng MH, Moses JW, Teirstein PS. Complications of percutaneous coronary intervention. In: Topol EJ, Teirstein PS, eds. Textbook of Interventional Cardiology. 7th ed. Philadelphia, PA: Elsevier; 2016:464-481.

9. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acutemyocardial infarction:a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20.

10. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J AmColl Cardiol. 2006;48(7):1319-1325.

11. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629-638.

12. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med. 2014;174(2):223-230.

13. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005;111(22):2906-2912.

14. Weiss S,WeintraubW. Revascularization vs medical therapy in stable ischemic heart disease. Prog Cardiovasc Dis. 2015;58(3):299-305.

15. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease andmyocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174(2):232-240.

16. Boden WE, O’Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516.

17. Boden WE, O’Rourke RA, Teo KK, et al;COURAGE trial coprincipal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program No. 424. Am Heart J. 2006;151(6):1173-1179.

18. WeintraubWS, Spertus JA, Kolm P, et al; COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677-687.

19. Shaw LJ, Berman DS, Maron DJ, et al; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283-1291.

20. Shaw LJ,WeintraubWS, Maron DJ, et al. Baseline stressmyocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J. 2012;164(2):243-250.

21. Kereiakes DJ, Teirstein PS, Sarembock IJ, et al. The truth and consequences of the COURAGE trial. J AmColl Cardiol. 2007;50(16):1598-1603.

22. Hilliard AA, From AM, Lennon RJ, et al. Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv. 2010;3 (2):172-179.

23. Frye RL, August P, Brooks MM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-2515.

24. De Bruyne B, Pijls NH, Kalesan B, et al; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991-1001.

25. De Bruyne B, Fearon WF, Pijls NH, et al; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371(13):1208-1217.

26. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/ HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J AmColl Cardiol. 2012;59(9):857-881.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024